

May 21, 1968





W. F. MULLER

3,384,080

PORTABLE SPRING POWERED INFUSION DEVICE HAVING ESCAPEMENT
MEANS CONTROLLING SPEED OF INFUSION

Filed Oct. 16, 1964

3 Sheets-Sheet 1



INVENTOR

WOLF F. MULLER

BY

Dayton R. Stemple, Jr.
ATTORNEY

May 21, 1968

W. F. MULLER

3,384,080

PORTABLE SPRING POWERED INFUSION DEVICE HAVING ESCAPEMENT
MEANS CONTROLLING SPEED OF INFUSION

Filed Oct. 16, 1964

3 Sheets-Sheet 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

INVENTOR

WOLF F. MULLER

BY

Dayton P. Stemple, Jr.
ATTORNEY

May 21, 1968

W. F. MULLER

3,384,080

PORTABLE SPRING POWERED INFUSION DEVICE HAVING ESCAPEMENT
MEANS CONTROLLING SPEED OF INFUSION

Filed Oct. 16, 1964

3 Sheets-Sheet 3




Fig. 9





Fig. 10

Fig. 10a




Fig. 12




Fig. 11

INVENTOR

WOLF F. MULLER

BY

Dwight R. Stemple, Jr.
ATTORNEY

1

3,384,080

**PORTABLE SPRING POWERED INFUSION DEVICE
HAVING ESCAPEMENT MEANS CONTROLLING
SPEED OF INFUSION**

Wolf F. Muller, New York, N.Y., assignor, by mesne assignments, to United States Catheter & Instrument Corporation, Glens Falls, N.Y., a corporation of Delaware
Filed Oct. 16, 1964, Ser. No. 404,425
4 Claims. (Cl. 128—214)

ABSTRACT OF THE DISCLOSURE

A portable infusion device for constantly injecting therapeutic fluids into the human body at low but positive pressures, which has a roller pump squeezing tubing containing medicaments for injection into the body. The pump is powered by a spring motor, the speed of which is controlled by a watch escapement unit connected by gearing to the spring motor.

This invention relates to new and useful improvements in portable infusion devices and more particularly seeks to provide a low pressure, positive force portable infusion device adapted especially for ambulatory intravascular drug therapy over an extended period of time, e.g. arterial infusion of antimetabolite drugs for regional chemical therapy of cancer.

A huge undertaking of cancer research is currently in progress to develop anticancer drugs for use in the management of neoplastic disease in man and an increasing number of compounds are becoming available for clinical use by the physician. Despite the prodigious efforts of these pre-clinical and clinical programs, progress has been slow and no chemical agents have been developed that are capable of inducing a general curative effect on disseminated forms of cancer. Nevertheless, over the past several years definite advances have been made in the introduction of new chemical compounds and special techniques and procedures of their administration for the chemical control of advanced cancer.

Methods of regional cancer chemotherapy have been developed to enhance the antitumor effect of compounds currently in use which, when given systemically, have been shown to have little practical value in the management of certain localized, yet uncontrolled, forms of cancer. A catheter is inserted into the accessible blood supply of the neoplasm and an antimetabolite is administered by continuous infusion for 1 week to 4 months or longer. For the most part, antimetabolites have been investigated by this method of administration, alone, and at times, combined with the appropriate metabolite administered systemically. The largest clinical experience has been with the antifolic compound, Methotrexate, and its antidote, citrovorum factor, as well as with the fluorinated pyrimidines, FU and FUDR. In general, when the disease has been limited to the area of infusion, the results have been good in terms of objective tumor regression and sustained clinical benefit. Antidote of the antimetabolite may be administered systemically to counteract distant toxic actions on bone marrow and intestine.

It is also apparent that these newer local techniques will become significant both in the research study of endocrine system function and in the therapy of endocrine disease. The ability to infuse a vascular bed bearing a target organ over a period of days gives one the ability to control the internal environment of that organ. Known concentrations of drugs can be introduced directly into vascular channels leading to the gland and chronic intermittent sampling of the venous drainage is possible.

It is desirable to prolong current forms of regional

2

cancer infusion therapy by the use of mechanism permitting, on ambulatory, outpatients basis, parenteral administration of fluid containing antimetabolite drugs. Such a mechanism would also prove valuable in the animal laboratory since it would permit the continuous parenteral infusion of drugs into unrestrained large animals, such as dogs.

In developing a mechanism for vascular infusion or other medical purposes, the output must be accurate, a low pressure and volume but at sufficient positive pressure to prevent backflow on the high systolic point of the blood pressure. For ambulatory, out-patient use, the mechanism must be light, simple, durable, dependable and entirely self-contained including the driving mechanism.

To maintain sterile conditions and maintain acceptable surgical techniques, the unit must be operable on a minimum of instructions to patients, not subject to breakdown, and readily transferrable to new patients without danger of contamination. There must be high torque slow revolution but overdrive to fill the unit in the beginning, and only uncostly disposable members that contact the medicament.

As disclosed hereinafter, the instant infusion device meets all these demands and requirements. A small portable unit attachable to a catheter contains a replenishable drug supply, positive pump driving means at low pressure and volume, easily and accurately measured output, and manual means for replenishing the power means.

With these features in view, the nature of which will be more apparent, the invention will be more fully understood by reference to the drawings, the accompanying detailed description, and the appended claims.

In the drawings:

FIG. 1 is a perspective view of the empty case from the medicament side;

FIG. 2 is a perspective view of the empty case from the driving side;

FIG. 3 is a plan view of the medicament side of the infusion device with all parts in position except the cover;

FIG. 4 is a plan view from the opposed driving side;

FIG. 5 is a section taken along line 5—5 of FIG. 3;

FIG. 6 is a perspective exploded view of the driving mechanism of FIG. 5;

FIG. 7 is a perspective view of the tubing part mounted in the arcuate track segment;

FIG. 8 is a plan view with a plate removed of the watch braking mechanism;

FIG. 9 is a perspective view of the winding key;

FIG. 10 and 10a are side and plan views respectively of the priming key;

FIG. 11 is a diagrammatic longitudinal section of the reservoir; and

FIG. 12 illustrates the filling of the reservoir.

As illustrated, this pump is designed primarily for precisely injecting small volumes of parenteral fluid during ambulatory intravascular therapy but obviously with or without modification may be used for many other purposes, including precise feeding during space flight, precise feeding for animal experiments, etc.

A rectangular cast aluminum case 50 has an irregular partition 49 dividing a medicament chamber 39 covered by an inner cover not shown from a driving chamber 55 covered by an outer cover not shown, the case having dimensions of about 5" x 2.25" x 1.25" and weighing about 340 grams when completed as described hereinafter. The drug reservoir 53 is located in medicament chamber 39 and the clock escapement mechanism 54 is in driving chamber 55, whereas the drive mechanism is rotatably mounted in aperture 16 and is thus

positioned in both chambers. The covers are, of course, readily removable by screws or otherwise.

The drive mechanism includes a mainspring 17 mounted and secured within cylinder 18 and secured at the other end to the winding hub 19 which is integral with base ratchet plate 41 and spindle 61. The base ratchet plate may be wound counterclockwise against the mainspring and is held from rotating clockwise by pawl 56 held in position by spring 57. Accordingly, the mainspring drives the cylinder 18 and associated gear 42. The gear 42 carries an enlarged hub 43 rotatably mounted on spindle 61 and a small ratchet 44. Rotatably mounted on hub 43 is a rotor including a smooth plate 46 spaced from gear 42 by a cylindrical wall 45 to enclose ratchet 44 and to carry a pawl 59 so that plate 46 can move only in the direction of gear 42. The rotor also includes four spindles 47 carried by plate 46 which terminate at their opposed ends in a priming gear 48. Rotatably mounted between plate 46 and gear 48 on spindles 47 and extending beyond the periphery thereof, are four nylon rollers 22 which are spaced about $\frac{1}{32}$ " from segment 23 for about 180° of plate 46 and gear 48 circle.

This segment 23 holds a short segment of silastic tubing 24 which passes from the plastic drug reservoir 53 by the pump rollers to deliver fluid to the catheter attached to a subject. It may be provided at one end with a hypodermic needle connector for puncture of a rubber diaphragm of the silastic drug reservoir, e.g. of 25 ml. volume, and at the other end with a conventional male Luer-lok or other connector for a catheter or other member. The tubing is fabricated with a solid ridge 26 along its outer side with a bore 27 for passage of the drug. This solid ridge is clamped firmly into the semi-circular metal track segment 23 to prevent slippage of the tubing as the rotor revolves. The track is fabricated of two semi-circular segments of metal which are screwed together and held in accurate alignment by studs 29, single screw 31, and crown 62 on aperture 16. Loosening of the holding screws permits slight separation of the two semi-circular segments and introduction of the solid ridge of the silastic tubing into the track.

The tubing 24 is provided with a grommet 32 that is secured to a notch 30 in the casing wall to prevent any external force from pulling the tube out of position. Starting slightly proximal to the grommet and extending to the peripheral end, the tubing is much thicker so that it will not reflect pulsations of the vascular system. At the proximal end of ridge 26 is located an enlarged bead 53 which is used to longitudinally position the tubing 24 relative to the track segment 23. The track-retaining screw 31 of the housing may be loosened sufficiently to permit introduction of the tubing 24 and metal track 23. The semi-circular metal track must pass beneath the upper flange of the retaining posts 29 at either end of the groove in the casing into which the semi-circular track fits. It should be possible to completely advance the track retaining screw so that the semi-circular metal track passes beneath each flange, thereby insuring that the pump will function by occlusive compression of the tubing by the pump rotors.

The rotor unit can rotate only counterclockwise under force of the mainspring or by positive force applied to the priming gear 48 as shown hereinafter. The rotor unit is driven ordinarily by the mainspring through gear 42, the speed of which is controlled by the clock escapement mechanism. Gear 42 drives first spur gear 64 which drives second spur gear 66 which drives third spur gear 67. The third spur gear drives the escapement wheel 35 controlled by the escapement arm 36 and the balance wheel 34. This is a conventional clock escapement with two movements of the arm permitted per second. This is translated through appropriate gear reduction so that the rotor makes a complete 360° revolution every hour which means that the volume of fluid pumped per hour is four times the internal bore volume of 90° of the tubing. The

tubing is carefully calibrated to give, for example, 0.05 cc. per 90°, or 0.2 cc. per hour or 4.8 cc. per day.

It will be obvious that the amount of drug to be pumped can be varied by changing speed of the watch mechanism, changing bore of the tubing or changing concentration of material in the bag, the latter being generally the most convenient.

The proximal end of tube 24 may be provided with a knurled and threaded penetrating needle 25 which is particularly adapted for a leak-proof connection with reservoir 53. Various types of reservoirs could be used but that shown herein has been found preferable. This bag has molded within the outlet end a metal disc 68 with an internally threaded aperture 69 within an outwardly extending hub 71 and channel 72. Into this channel and also bulging outwardly is an integral part of the bag plastic to form a sealing hub 73 whereby the needle flange 74 is threaded down to provide a leak-proof secondary seal, there being a primary seal inside the bag where the needle point penetrates the internal plastic layer of the bag. The inlet or filling end of the bag includes a metallic collar 76 with partly circular and partly straight flange 77, a threaded aperture 78, a sealing hub 79 extending beyond the collar 76 and a plastic screw cap 81 which threads down to make a positive seal with hub 79.

It is desirable that the bag 53 be filled completely so that no air can be introduced into the system. This is done by holding the bag with holder 82 and introducing the medicament to the bottom with a syringe 83 as shown in FIG. 12. When the bag has been completely filled, the screw cap is threaded into aperture 78 before the bag is touched manually. If the bag is touched before closing, some squeezing will occur which diminishes the bag volume and subsequently draws air into the bag.

These filled bags may be provided to the patient as disposable units to be discarded after a single use or they may be returned for refilling. In either event, there should be no leakage into the housing or contamination thereof.

Once needle 25 has been properly inserted in bag 53, it is necessary to fill the line through tubing 24 and an attached catheter or it may be necessary to flush the line with saline. Since the rotor unit rotates once per hour, this is not practical. However, priming key 37 is placed in aperture 84 of plate 86 to connect with priming gear 48 whereupon the rotor may be advanced at will for priming or flushing purposes.

The winding key 38 or stem threads into winding hub 19 to tighten the mainspring 17 to force gear 42 counterclockwise against the speed control of the clock escapement mechanism. Both the priming and winding keys are detachable. The mainspring is generally calculated to run twelve hours if completely wound. In any event, the patient can hear the ticking of the clock mechanism and will then know when the unit must be rewound.

The pump tubing (with attached metal track and adapters) and the disposable plastic drug reservoirs are the only parts of the device which need to be sterilized. Generally the tubing and reservoir will both be discarded when changing pumps from one patient to another so that the metal segment 23 is the only part that requires sterilization.

A harness is available so that the device can be strapped to the front of the chest. The winding hub 19 is directed outward so that the winding stem can be inserted without removal of the device from the harness case.

I claim:

1. A small-volume, positive-pressure, self-contained infusion device intended to be carried on the human body and adapted for constantly and slowly infusing desired liquids into the vascular system comprising a housing, an arcuate inflexible member secured inside said housing, an arcuate segment of flexible tubing mounted on the inner surface of said arcuate inflexible member and adapted

5

to be attached to a liquid reservoir and a catheter at the opposite ends thereof, a rotor mounted with its periphery parallel to and spaced from said arcuate inflexible member, a plurality of rollers mounted on the periphery of said rotor and extending outward to a point adjacent said inflexible member, a tooth gear operably engaged with said rotor, a convolute mainspring operably engaged to drive said gear, means to wind said spring, and a watch escape-ment unit driven by said gear to control the speed thereof.

2. The device of claim 1 additionally comprising said reservoir positioned within said housing.

3. The device of claim 1 wherein said rotor includes a ratchet mechanism permitting rotation of one portion manually in order to prime or flush said tube.

4. The device of claim 1 additionally comprising a primary crank for manual rotation of said rotor and a winding crank to wind said mainspring.

5

10

15

6

References Cited

UNITED STATES PATENTS

2,188,507	1/1940	Harris	222—7
2,483,924	10/1949	Moulinier	103—14
2,668,637	2/1954	Gilmore	222—9
2,703,084	3/1955	Tomlinson	128—21
3,048,171	8/1962	Grau	128—214.
2,761,445	9/1956	Cherkin	128—21
3,137,242	6/1964	Hahn	103—15
3,165,238	1/1965	Wiley	222—7

FOREIGN PATENTS

1,001,908 10/1951 France.

DALTON L. TRULUCK, *Primary Examiner.*